Finally, the anti-hemorrhagic agent with clinical trial was fostamatinib, which had an AUROC affinity of 1.0 on EGFR, and it is an inhibitor of spleen tyrosine kinase used to treat chronic immune thrombocytopenia (Supplementary Table S10; Wishart et al., 2018). The gene discussed is SYK; the disease is autoimmune thrombocytopenic purpura.